Oculis Holding AG (OCS)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Riad Sherif M.B.A., M.D. | CEO & Director | -- | -- | 1968 |
| Ms. Sylvia Cheung | Chief Financial Officer | -- | -- | 1975 |
| Ms. Gudrun Bachmann Ph.D. | Chief Technology Officer | -- | -- | -- |
| Dr. Ramin Tadayoni M.D., Ph.D. | Chief Scientific Officer | -- | -- | -- |
| Mr. Daniel S. Char J.D. | Chief Legal Officer | -- | -- | 1961 |
| Ms. Virginia R. Dean | Chief Human Resources Officer | -- | -- | 1967 |
| Mr. Páll Ragnar Jóhannesson | Chief Business Officer | -- | -- | 1982 |
| Ms. Rebecca Weil | Chief Commercial Officer | -- | -- | -- |
| Dr. Snehal Shah Pharm.D. | President of Research & Development | -- | -- | -- |
| Dr. Sharon Klier M.D., M.P.H. | Chief Development Officer | -- | -- | -- |
Oculis Holding AG
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 49
Description
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
September 4, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission